Related Experiment Video

Updated: May 3, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer

Athanasia Pavlidou1, Nikos F Vlahos2

  • 1Second Department of Obstetrics and Gynecology, University of Athens Medical School, Aretaieion University Hospital, 76 Vas. Sofias Avenue, 11527 Athens, Greece.

Thescientificworldjournal
|February 15, 2014
PubMed

Insights

The PI3K/Akt/mTOR pathway is crucial for cell growth and is frequently altered in endometrial cancer. Identifying key pathway steps and targeting mTOR may lead to new endometrial cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • The Phosphatidylinositol 3-kinase/Akt/Mammalian Target of Rapamycin (PI3K/Akt/mTOR) pathway regulates fundamental cellular processes like growth and proliferation.
  • Deregulation of the PI3K/Akt/mTOR pathway is implicated in various cancers, including endometrial cancer.
  • Genetic alterations within this pathway are common in endometrial malignancies.

Purpose of the Study:

  • To review genetic alterations in the PI3K/Akt pathway associated with endometrial cancer development.
  • To identify critical rate-limiting steps within this pathway for therapeutic targeting.
  • To present potential therapeutic targets, focusing on mTOR inhibitors for endometrial cancer.

Main Methods:

  • Literature review of genetic alterations in the PI3K/Akt pathway in endometrial cancer.
  • Analysis of the role of pathway components in endometrial carcinogenesis.
  • Identification and discussion of potential therapeutic targets, including mTOR inhibitors.

Main Results:

  • The PI3K/Akt/mTOR pathway is frequently altered in endometrial cancers.
  • Specific genetic alterations contribute to the pathway's dysregulation in this cancer type.
  • mTOR inhibitors represent a promising therapeutic strategy.

Conclusions:

  • Understanding PI3K/Akt pathway alterations is vital for developing targeted endometrial cancer therapies.
  • Targeting the PI3K/Akt/mTOR pathway, particularly with mTOR inhibitors, offers potential for novel treatment strategies in endometrial cancer.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K